Kymera Therapeutics director Albers sells $295k in shares

Director Jeffrey W. Albers of Kymera Therapeutics (NASDAQ:KYMR) sold 5,000 shares of common stock on October 13, 2025, for a total of $295,949. The shares were sold at a weighted average price of $59.1898, with individual sales prices ranging from $59.00 to $59.42. The transaction comes as KYMR trades near its 52-week high of $60, having surged over 135% in the past six months. InvestingPro analysis indicates the stock is currently in overbought territory.

On the same day, Albers also exercised options to purchase 5,000 shares of Kymera Therapeutics common stock at an exercise price of $10.34, for a total value of $51,700.

The transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on September 20, 2024.

In other recent news, Kymera Therapeutics has been the focus of several analyst updates and coverage initiations. Stifel has reiterated a Buy rating on Kymera Therapeutics, setting a price target of $68 ahead of key Phase 1b data for its STAT6-degrader, KT-621, in atopic dermatitis. Truist Securities also raised its price target for the company to $68, following a virtual event with Kymera’s CEO and CMO, projecting approximately $1.9 billion in peak adjusted sales for KT-621. H.C. Wainwright increased its price target to $70, maintaining a Buy rating after Kymera presented comprehensive data at EADV 2025 for KT-621. Barclays initiated coverage with an Overweight rating and a $60 price target, citing promising early clinical data for KT-621. Additionally, RBC Capital began coverage with an Outperform rating and a $70 price target, expressing confidence in the drug’s potential based on early proof of concept data. These developments highlight the growing interest in Kymera’s lead asset, KT-621, among analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.